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U.S. SEER (Surveillance Epidemiology and End Results) data for age-adjusted mortality
rates for all cancers combined for all races show only amodest overall 13% decline over the
past 35 years. Moreover, the greatest contributor to cancer mortality is treatment-resistant
metastatic disease. The accepted therapeutic paradigm for the past half-century for the
treatment of advanced cancers has involved the use of systemic chemotherapy drugs
cytotoxic for cycling cells (both normal and malignant) during DNA synthesis and/or
mitosis. The failure of this therapeutic modality to achieve high-level, consistent rates of
disease-free survival for some of the most common cancers, including tumors of the lung,
colon breast, brain, melanoma, and others is the focus of this paper. A retrospective
assessment of critical milestones in cancer chemotherapy indicates that most successful
therapeutic regimens use cytotoxic cell cycle inhibitors in combined, maximum tolerated,
dose-dense acute treatment regimens originally developed to treat acute lymphoblastic
leukemia and some lymphomas. Early clinical successes in this area led to their wholesale
application to the treatment of solid tumor malignancies that, unfortunately, has not
produced consistent, long-term high cure rates for many common cancers. Important
differences in therapeutic sensitivity of leukemias/lymphomas versus solid tumors can
be explained by key biological differences that deﬁne the treatment-resistant solid tumor
phenotype. A review of these clinical outcome data in the context of recent developments
in our understanding of drug resistance mechanisms characteristic of solid tumors
suggests the need for a new paradigm for the treatment of chemotherapy-resistant
cancers. In contrast to reductionist approaches, the systemic approach targets both
microenvironmental and systemic factors that drive and sustain tumor progression. These
systemic factors include dysregulated inﬂammatory and oxidation pathways shown to
be directly implicated in the development and maintenance of the cancer phenotype.
The paradigm stresses the importance of a combined preventive/therapeutic approach
involving adjuvant chemotherapies that incorporate anti-inﬂammatory and anti-oxidant
therapeutics.
Keywords: anti-inflammatory, anti-oxidant, tumor microenvironment, chemotherapy, adjuvant, drug resistance,
neoplasm
INTRODUCTION
Anewparadigm to guide cancer treatment researchmay be needed
in this 21st century, one that builds upon the previous century of
research and discovery on the nature of this very complex and
still mysterious disease. An exploration of the highlights and dif-
ﬁculties encountered in the long quest to understand the systemic
treatment of cancermay provide a necessary perspective so that we
can move forward to realize the long anticipated goal of ﬁnding a
meaningful and permanent solution to the cancer problem. As the
so-called “War on Cancer” rapidly approaches the half-century
mark, there has been a lot of discussion about its successes and
failures. It is not the purpose of this discussion to elaborate on
the political or economic aspects of cancer research, but rather
to approach the issue from the standpoint of a very basic scien-
tiﬁc inquiry of what we have learned from a century of cancer
research with respect to future potential translational and clinical
applications.
Cancer chemotherapy emerged as ameans for treating systemic
disease in the 1960s. Prior to this time, the primary treatment
for cancer involved surgery and radiation. Neither therapeutic
modality was designed to treat the problem of systemic diseases
due to metastasis. This limitation ultimately became the rationale
for a new therapeutic approach to deal with the systemic nature
of this disease, eventually involving the use of cytotoxic drugs.
Before the advent of systemic treatment, the long-term remission
rates for cancers across-the-board could not be pushed beyond
approximately 35%, and this difﬁculty, of course, generated much
interest in developing systemic approaches that would produce
greater cure rates.
The focus of this paper is speciﬁcally the biological aspects of
cancer therapeutics that comprise the core components of ther-
apeutic responses -both positive and negative- to conventional
cytotoxic chemotherapy drugs. This involves an assessment
of current chemotherapy modalities and how these therapy
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approaches may need to be modiﬁed in an attempt to
develop novel therapeutics for the treatment of refractory
cancers.
CANCER THERAPEUTICS 2013: HOW ARE WE DOING?
The assessment of cancer statistics: incidence, mortality, and ther-
apeutic efﬁcacy can be a fairly difﬁcult and detailed exercise as
one attempts to elucidate these important quantitative parame-
ters of the collection of diseases we call cancer. This quest has
perhaps been made even more complicated by the various termi-
nologies that have evolved in evaluations used to assess clinical
data, including disease-free survival, time to disease recurrence,
overall response rates, and partial/complete responses, to name
a few. Despite these complexities, any reading of current can-
cer statistics suggests that, although there has been signiﬁcant
progress over the past half-century in understanding the basic
biology of cancer, the genetics of cancer, and the development
of better diagnostic and therapeutic approaches, a consensus of
researchers, both basic and clinical, would most likely agree that,
in the year 2013, we are not where we would like to be in terms
of developing a rational and broadly applicable means of treat-
ing many of the most common types of cancer that respond
poorly and/or inconsistently to current standard of care treat-
ment approaches. It is beyond the scope of this discussion to
present a detailed review of the current statistics; sufﬁce it to
say that for many of the most common cancers, including lung
cancer, breast cancer, colon cancer, and some of the less com-
mon, but, nonetheless, very serious cancers, such as pancreatic
cancer and brain cancer, the statistics on successful therapeutic
responses have not met with the expectations engendered by the
enormous progress in cancer molecular genetics that was made
in the latter part of the 20th century (see Figures 1–4). Figure 1
shows the age-adjusted mortality rates for all cancers combined,
all ages, all races, and both sexes in the U.S. between 1975 and
2009. The SEER (Surveillance Epidemiology and End Results)
data show that the approximate percent decline in mortality rates
from all cancers combined has decreased by approximately 13%
over the past 40 years (Howlader et al., 2011). Figure 2 shows
the age-adjusted mortality rates for some of the most common
cancer sites for all races all genders from 1975 to 2009. Figure 3
shows mortality rates in women all races for common cancers
such as breast and ovarian. Figure 4 shows age-adjusted mor-
tality rates for common cancers in men all races for this time
period.
It is not the purpose of this discussion to elaborate in depth
on the speciﬁc statistics associated with any particular type of
cancer; rather, the focus is to explore in a more general sense
what the successes and difﬁculties of cancer chemotherapy have
been over the past 50 years with an eye toward assessing what
needs to change in order to make the most of the tremendous
scientiﬁc resources afforded by the molecular biology advances
of the last half-century. There is no doubt that more progress
is needed as patient responses to chemotherapy are generally
variable even within a single type of cancer and that the term
“cure” is one that is only very carefully applied as we look
at the potential successes and efﬁcacies of various therapeutic
approaches.
FIGURE 1 | Age-adjusted mortality rates for all cancers combined, US
SEER data (Howlader et al., 2011).
CANCER CHEMOTHERAPY: WHAT DOES HISTORY TELL US?
The treatment of systemic cancers using chemotherapy drugs as
a major component of cancer therapeutics began with an early
observation made by Beatson (1896) on the effect of estrogens on
breast cancer that was noted many years later by Charles Huggins,
who was the ﬁrst to treat men with prostate cancer by castration
to block hormone-mediated effects on prostate cancer cells, an
approach that resulted in improved patient outcome (Huggins and
Hodges, 1941). The historical origins of cytotoxic chemotherapy
as a form of systemic cancer treatment began with observations
of the physiological effects of agents of chemical warfare such as
mustard gas used in World Wars I and II (Gilman, 1946). Clin-
ical studies of soldiers exposed to these agents, followed up by
laboratory research in rabbits showed that, among other noxious
effects, this type of chemical exposure resulted in the suppression
of bone marrow cell proliferation, suggesting a potential clinical
application to the treatment of leukemias and lymphomas.
The ﬁrst human experiments on the use of nitrogenmustard as
a cancer chemotherapeutic agent were reported inChicago in 1943
(Gilman, 1963) when a patient with non-Hodgkin’s lymphoma
(NHL) was treated with nitrogen mustard, which produced a dra-
matic alleviation of disease symptoms. This success ultimately
led to the development of other cytotoxic drugs based on the
use of nitrogen mustard; these included alkylating compounds
such as chlorambucil and cyclophosphamide. These early ﬁndings
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FIGURE 2 | Age-adjusted mortality rates for specific cancer types in
males and females, all races combined, US SEER data (Howlader et al.,
2011).
led to the notion of a potential medical use for these agents in
the treatment of bone marrow-based blood disorders such as
leukemia. The earliest clinical trials were begun in 1946, which
represents the beginnings of modern cancer chemotherapy. The
ﬁrst patients were treated with nitrogen mustard gas derivatives,
such as myloran and chlorambucil, that produced transient treat-
ment responses that, unfortunately, were followed by inevitable
relapses (see below; Goodman et al., 1946).
Some of the most common chemotherapy drugs used today
were originally developed as antibiotics intended for use in the
treatment of infectious disease. However, some of these antibi-
otics were found to be too toxic because of their effects on the
bone marrow and intestinal lining and were later re-purposed
as anti-cancer drugs. For example, para-amino benzoic acid
(PABA) derivatives used in cancer chemotherapy were originally
developed as anti-microbial sulfa drugs to treat infectious dis-
eases such as streptococcal infections (Pinkel, 1959). This concept
that anti-microbial antibiotics could be used also or alternatively
as anti-cancer drugs led to the development and the synthe-
sis of the anti-folate antagonists aminopterin and amethopterin
(methotrexate; Farber, 1949; Law et al., 1949). These were the ﬁrst
FIGURE 3 | Age-adjusted mortality rates for specific cancer types in
females, all races combined, US SEER data (Howlader et al., 2011).
drugs to induce temporary remissions of childhood acute lym-
phoblastic leukemia (ALL) as early as 1948 (Farber et al., 1948)
and also produced the ﬁrst cures of gestational choriocarcinoma a
few years later (Li et al., 1958; Hertz et al., 1963).
These early successes with childhood ALL and choriocarci-
noma became the model for the further development of cytotoxic
chemotherapy drugs for the treatment of many types of cancer.
The ﬁrst antibiotic developed to take advantage of its anti-tumor
properties, 6-mercaptopurine, was discovered in 1948 and devel-
oped into a class of purine and pyrimidine antagonists that
ultimately were used in the treatment of childhood ALL in the
1950s and 1960s (Elion et al., 1954; Hitchings and Elion, 1954;
Frei et al., 1961; George et al., 1968). The drug 5-ﬂuorouracil was
discovered at about the same time and was later found to be active
against a number of solid tumormalignancies (Heidelberger et al.,
1957; see Figure 5). Other anti-cancer agents developed in this
trial and error approach include the vinca alkaloids that function
as anti-mitotic agents (Johnson et al., 1963).
The development of many important cytotoxic drugs was the
result of an effort to identify natural and synthetic compounds
with anti-cancer activity via mass screenings for their anti-cancer
effects in vitro on cultured tumor cell lines. Anti-cancer drugs
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FIGURE 4 | Age-adjusted mortality rates for specific cancer types in
males, all races combined, US SEER data (Howlader et al., 2011).
developed using this trial and error approach include paclitaxel,
ﬂudarabine, BCNU, carboplatin, cytosine arabinoside pentastatin,
hydroxyurea, topotecan, andmitoxantrone (Marshall, 1964).Most
of these are still in widespread use today (see Figure 6). Their
extraordinary efﬁcacy in the treatment of select cancer types,
such as ALL, some types of lymphoma and testicular cancer, is
undisputed; nevertheless, the success rate of traditional cytotoxic
chemotherapy in producing long-term patient disease-free sur-
vival is unpredictable, and in many cancers, unsatisfactory. Based
on this clinical record of a half-century of widespread use, it is
essential to address the problem of broad-spectrum clinical efﬁ-
cacy of standard chemotherapy in order to maximize its clinical
beneﬁt in treatment of cancers most likely to respond to this
therapeutic approach.
PROBLEMS WITH CYTOTOXIC CHEMOTHERAPY:
HISTORICAL LESSONS
Very early in the history of cancer chemotherapy, clinical trials
producing rapid remissions in patients with ALL and Hodgkin’s
disease (HD) were followed by the disappointing recurrence of
treatment-resistant disease, soon to be identiﬁed as one of the
most intractable problems associated with cancer chemotherapy
FIGURE 5 | Development of a successful combined chemotherapy
approach for childhood acute lymphoblastic leukemia (ALL) that
ultimately became a therapeutic model for the treatment of systemic
cancers of many types. In 2012 the cure rate for childhood ALL is 90%.
(Photo: Archive St. Jude’s Hospital). “November 12, 1970 – Dr. Rhomes J.
A. Aur, of St. Jude Children’s Research Hospital, with Steven Ray of
Jackson, Miss. who has been receiving treatment for leukemia for 2 years.
Announcement of a 17% cure rate in leukemia was made at the hospital
today.”
(Hertz et al., 1963; Skipper et al., 1965; Skipper and Perry, 1970).
Just as Alexander Fleming noted the growth of penicillin-resistant
bacteria in early studies with this antibiotic that presaged the
extraordinary clinical problem of antibiotic-resistant “superbugs,”
early clinical studies of chemotherapy drugs in cancer patients
revealed a similar resistance phenomenon that was to plague the
efﬁcacious use of these drugs in the treatment of cancer. Prob-
lems associated with their therapeutic efﬁcacy noted from their
inception were initial positive treatment responses or remissions
that were too often followed by the recurrence of disease that was
frequently insensitive to the therapeutic effects of the agent origi-
nally used to achieve remission. The term for this phenomenon is
“acquired drug resistance.”
Bacterial drug resistancemechanismswere found to result from
antibiotic resistance genes that can spread rapidly in populations
of bacterial cells and whose presence can be ampliﬁed by the
selective destruction of bacteria that do not contain these genes,
resulting in the “natural selection” of drug-resistant colonies of
infectious agents within the body. The same principle has been
observed to be responsible for the development of drug-resistant
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FIGURE 6 | US SEER data on mortality rates of several leukemias and
Hodgkin’s lymphoma that have seen a precipitous decline since 1975
resulting from dose-dense combined chemotherapy MTD therapies
(Howlader et al., 2011).
cancer cells; in some cases, drug resistance appears to result
from the selection of tumor phenotypes produced by genetic
mutations (generally gene ampliﬁcations) that confer resistance
to the cell killing effects of speciﬁc types anti-cancer drugs,
such as the ampliﬁcation of the mdr-1 gene, associated with
a multi-drug-resistant phenotype and the dihydrofolate reduc-
tase (DHFR) gene, which speciﬁcally confers resistance to the
folate antagonists (e.g., methotrexate; Schimke, 1988). Thus, one
major issue that has emerged from over half a century of use
of anti-proliferative chemotherapy drugs is the problem of drug
resistance.
This problem has its origins in the genetic instability that is
a hallmark of abnormal tumor growth, in which random genetic
changes associatedwith dysregulated proliferativemechanisms are
the harbingers of the development of novel genotypes with the
capacity to evolve to drug-resistant phenotypes. This is unlike
normal dividing cells of the body in which the genetic stabil-
ity of the cells precludes the development of drug resistance.
Malignant cells in general tend to be less stable genetically than
normal cells, a phenotype in part associated with dysregulated
proliferation (Leach et al., 1993; Kennedy and D’Andrea, 2006).
Genetic instability allows for the establishment of drug-resistant
clones based upon genetic mechanisms of acquired drug resis-
tance. This phenomenon has provided a rationale for the develop-
ment of combined, high-dose therapeutic regimens that, in some
types of cancer, have been able to prevent the development of
acquired resistance (DeVita and Schein, 1973; DeVita et al., 1975;
Leach et al., 1993; Rajagopalan and Lengauer, 2004; Kennedy and
D’Andrea, 2006).
THE WAR AGAINST DRUG RESISTANCE LEADS TO NEW
CHEMOTHERAPY CLINICAL REGIMENS
In order to bypass this serious clinical issue of drug resistance due
to genetic instability, the concept of “combined chemotherapy”
evolved, based upon the notion that a combination of drugs with
non-overlapping mechanisms of action could prevent or delay
the emergence of drug-resistant tumor cells and result in greater
overall sensitivity to the cell killing effects of these drugs. The
need to prevent drug resistance also led to the development of
the concepts of dose intensity and high-dose chemotherapy. Dose
intensity refers to a cumulative dose within a speciﬁed amount of
time involving the maximum tolerated dose (MTD). The concept
of dose intensity was based on the observation that patients with
HD who received lower dose chemotherapy showed lower cure
rates (DeVita and Schein, 1973). Additional, similar observations
in patientswith breast cancer and colon cancer ultimately led to the
application of potentially lethal doses of chemotherapy as a general
therapeutic approach to systemic cancers in the hopes of achieving
better therapeutic responses (Sparano et al., 2008; Bookman, 2009;
Katsumata et al., 2009).
The rationale for these therapeutic approaches was an effort
to achieve a maximal and rapid cell killing effect to over-
whelm the drug-resistant potential of genetically unstable tumors.
To achieve this therapeutic goal, these drugs were delivered
at MTDs. This latter approach involves the concept that the
higher the dose the greater the therapeutic efﬁcacy and the
lower the probability that drug-resistant mechanisms will have
the opportunity to develop. This concept led to therapeutic regi-
mens of dose intensity and high-dose chemotherapy in the hope
of achieving higher cure rates in advanced cancers of many
types (DeVita et al., 1975). With the publication of clinical trial
results using combined and high-dose therapeutic regimens, it
became clear that combined high-dose cytotoxic chemotherapy
treatment could cure cancer (Li et al., 1969; Bookman, 2009;
Bonilla et al., 2010).
After a further 25 years of trial and error, it was possible for
oncologists to optimize the use of these chemical agents in order
to induce long periods of disease-free survival for some types of
cancer. High-dose regimens and combined treatment protocols
were developed initially for the treatment of childhood leukemia
(ALL). The most effective was the VAMP protocol: vincristine,
amethopterin, 6-mercaptopurine and prednisone. This therapeu-
tic “cocktail” was administered intermittently to patients to allow
for bone marrow recovery. This treatment regimen led to an
increase in the rate of remission to 60% by the end of the 1960s
(Freireich et al., 1964; Zuelzer, 1964; Frei et al., 1965; Burchenal,
1966; Pinkel et al., 1971).
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Another cancer to respond to this therapeutic approach was
advancedHD. In the 1960s advancedHDwas usually fatal. Remis-
sions were attainable in only 25% of patients; however, disease
recurrence was the inevitable result using single agent protocols.
The development of the MOMP protocol combining nitrogen
mustard with vincristine, methotrexate, and prednisone (which
became the MOPP program which omitted methotrexate and
replaced it with procarbazine) generated complete remissions at
a rate of over 80% with 60% of patients avoiding any relapse of
this disease. These clinical results were published in 1965–1967
(DeVita et al., 1965, 1970, 1972; DeVita and Serpick, 1967; Mox-
ley et al., 1967). Beginning in 1975, patients with diffuse large
B cell lymphoma showed positive results using a similar proto-
col that substituted cyclophosphamide for nitrogen mustard. By
1984, mortality from childhood leukemia and HD had fallen by
65% (Papac, 2001). To optimize the therapeutic window, inten-
sive intermittent treatment cycles were given over a series of days
to allow recovery of normal proliferating bone marrow cells.
These therapeutic regimens led to one of the great success sto-
ries of chemotherapy, resulting in dramatic decreases in mortality
from the most common form of childhood leukemia (ALL) and
lymphoma (HD; see Figure 6).
With respect to solid tumormalignancies, it was clear thatmost
patients with local regional disease showing no sign of systemic
spread would, nevertheless, inevitably relapse using approaches
(surgery and radiation) that target only the site of the original
tumor (Greenspan et al., 1963; Canellos et al., 1974a,b). This was
clear both in the case of breast cancers as well as in colon and other
cancers. Despite the fact that a signiﬁcant fraction of patients with
local regional disease do not relapse, the rationale for the use of
adjuvant chemotherapy as an adjunct to local regional treatments
was the evidence that the percentage of patients relapsingwould be
high in the absence of adjuvant systemic therapy (Budman et al.,
1998; Fisher et al., 1999).
Clinical support for the rationale that combined chemother-
apy could be useful in the treatment of solid tumors resulted from
clinical results obtained in the 1960s and 1970s indicating that
combined chemotherapy could cure some types of advanced can-
cer (DeVita and Schein, 1973). Theoretical support for adjuvant
chemotherapy was provided by Skipper’s cell kill hypothesis sug-
gesting that, if tumors were treated at the level of micro-metastases
rather than as larger volume tumors, it would be more likely
that treatment would be effective (Skipper and Perry, 1970; Sch-
abel, 1975). These early successes in the 1960s and 1970s led to
the widespread application of these approaches to many differ-
ent types of human cancers, including many types of solid tumor
malignancies.
One of the ﬁrst adjuvant chemotherapy approaches in the treat-
ment of solid tumors combined cyclophosphamide,methotrexate,
and 5-ﬂuorouracil as an adjuvant chemotherapy for patients with
metastatic cancer [the CMF (Cyclophosphamide Methotrexate
Fluorouracil) regimen]. The overall response rate was over 50%;
about 20% of patients showed complete remissions. The CMF
study was published in 1976 with positive results (Canellos et al.,
1974a; Bonadonna et al., 1976).
Testicular cancer remissions went from 10 to 60% starting in
1978 using a combination of cisplatin, elastin, and bleomycin (Li
et al., 1969; Einhorn and Donohue, 1977, 1979). A notable suc-
cessful application of this approach is the use of the PVB protocol
(platinum, vinblastine, bleomycin) combined chemotherapy for
testicular cancer (Einhorn, 1981). A large number of additional
studies on adjuvant therapy for breast cancer as well as other
cancers such as colon cancer produced positive results that con-
tributed to a modest decline in U.S. mortality from breast cancer,
ovarian cancer, and others (Sparano et al., 2008; Bookman, 2009;
Katsumata et al., 2009; Bonilla et al., 2010).
For the past several decades, the prevailing therapeutic
paradigm for the treatment of both disseminated leukemias/
lymphomas as well as almost all solid tumor malignancies
has involved the use of dose-dense, combined MTD cytotoxic
chemotherapy to mitigate the problem of drug resistance. Despite
these broad-spectrum applications to almost all currently used
chemotherapy regimens, in only a few types of cancer do we
see curative responses such as have been consistently observed
in the treatment of childhood ALL and HD (see Figures 2–4).The
results of over a half-century of clinical trials have shown that
the therapeutic approach of combined/dose-dense chemotherapy
has not been entirely successful in achieving its primary purpose,
which is the induction of long-term disease-free survival in the
majority of patients with systemic disease (Kaufmann et al., 2011).
Thus, the rational use of these conventional chemotherapy treat-
ment protocols is challenged by the failure to observe consistent
results associated with long-term remissions of many common
cancers. Moreover, these clinical data indicate that the problem of
chemotherapy resistance is greater than that deﬁned by acquired
drug resistancemechanisms which would account for the inability
of dose-dense, combinedMTD approaches to provide greater efﬁ-
cacy in combating this problem. Research in solid tumor biology
suggests a more fundamental cause for chemotherapy resistance
involving biological mechanisms intrinsic to the cancer pheno-
type that are directly responsible for the limited efﬁcacy of these
current chemotherapy approaches to the treatment of solid tumor
malignancies. The primary reason for treatment failure can be
found in the biological properties of themalignant system, termed
“intrinsic resistance.”
LEUKEMIAS, SOLID TUMORS, MAXIMUM TOLERATED
GROWTH, AND THE “CELL KILL” PARADIGM
The mechanism of both phase speciﬁc and non-phase speciﬁc
chemotherapy drugs (which encompasses the vast majority of
cytotoxic chemotherapy drugs in current clinical use) is to tar-
get dividing cells (Kinzler andVogelstein, 1998). Most of the drugs
currently used in cancer chemotherapy were developed between
the years of 1953 and 1983. Today, there aremore than 75 Food and
Drug Administration (FDA) approved anti-cancer drugs. Almost
all of these are cytotoxic drugs that share a similar mechanism of
action to the extent that their toxic effects are speciﬁcally targeted
to dividing cells, due to interference with DNA metabolism or
mitosis (see Table 1).
Their mechanisms of action, therefore, do not distinguish
between normal and cancerous proliferating cells, a primary cause
of side effects such as bonemarrow suppression and dose-limiting
toxicities. The net result is a fairly narrow therapeutic window
between anti-tumor effect and MTD. These chemotherapy drugs
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Table 1 | A list of commonly used cytotoxic chemotherapy drugs that block DNA metabolism or cell division (mitosis) along with their most
common clinical indications and side effects (NCCN.com, the National Comprehensive Cancer Network)®.
Chemotherapy drug Possible side effects
(Not all side effects are listed. Some of those listed may be short-term side
effects; others are long-term side effects)
Carboplatin (paraplatin)
Usually given intravenously (IV) – used for cancers of the ovary, head
and neck, and lung
Decrease in blood cell counts, hair loss (reversible), confusion, nausea, vomit-
ing, and/or diarrhea (usually a short-term side effect occurring the ﬁrst 24–72 h
following treatment)
Cisplatin (platinol, platinol-AQ)
Usually given intravenously (IV) – used for cancers of the bladder,
ovary, and testicles
Decrease in blood cell counts, allergic reaction, including a rash and/or labored
breathing, nausea and vomiting that usually occurs for 24 h or longer, ringing in
ears and hearing loss, ﬂuctuations in blood electrolytes, kidney damage
Cyclophosphamide (Cytoxan, Neosar)
Can be given intravenously (IV) or orally – used for lymphoma, breast
cancer, and ovarian carcinoma
Decrease in blood cell counts, nausea, vomiting, abdominal pain, decreased
appetite, hair loss (reversible), bladder damage, fertility impairment, lung or heart
damage (with high doses), secondary malignancies (rare)
Doxorubicin (adriamycin)
Given intravenously (IV) – used for breast cancer, lymphoma, and
multiple myeloma
Decrease in blood cell counts, mouth ulcers, hair loss (reversible), nausea and
vomiting, heart damage
Etoposide (VePesid)
Can be given intravenously (IV) or orally – used for cancers of the
lung, testicles, leukemia, and lymphoma
Decrease in blood cell counts, hair loss (reversible), nausea and vomiting, allergic
reaction, mouth ulcers, low blood pressure (during administration), decreased
appetite, diarrhea and abdominal pain, bronchospasm, ﬂu-like symptoms
Fluorouracil (5-FU)
Given intravenously (IV) – used for cancers of the colon, breast,
stomach, and head and neck
Decrease in blood cell counts, diarrhea, mouth ulcers, photosensitivity, dry skin
Gemcitabine (Gemzar)
Given intravenously (IV) – used for cancers of the pancreas, breast,
ovary, and lung
Decrease in blood cell counts, nausea and vomiting, fever and ﬂu-like symptoms,
rash
irinotecan (Camptosar)
Given intravenously (IV) – used for cancers of the colon and rectum
Decrease in blood cell counts, diarrhea, hair loss (reversible)
Methotrexate (Folex, Mexate, Amethopterin)
May be given intravenously (IV), intrathecally (into the spinal
column), or orally – used for cancers of the breast, lung, blood,
bone, and lymph system
Decrease in blood cell counts, nausea and vomiting, mouth ulcers, skin rashes
and photosensitivity, dizziness, headache, or drowsiness, kidney damage (with
a high-dose therapy), liver damage, hair loss (reversible), seizures
Paclitaxel (Taxol)
Given intravenously (IV) – used with cancers of the breast, ovary,
and lung
Decrease in blood cell counts, allergic reaction, nausea and vomiting, loss of
appetite, change in taste, thin or brittle hair, joint pain (short-term), numbness or
tingling in the ﬁngers or toes
Topotecan (Hycamtin)
Given intravenously (IV) – used for cancers of the ovary and lung
Decrease in blood cell counts, diarrhea, hair loss (reversible), nausea and vomiting
Vincristine (Oncovin, Vincasar PFS)
Usually given intravenously (IV) – used for leukemia and lymphoma
Numbness or tingling in the ﬁngers or toes, weakness, loss of reﬂexes, jaw pain,
hair loss (reversible), constipation or abdominal cramping
Vinblastine (Velban)
Given intravenously (IV) – used for lymphoma and cancers of the
testis and head and neck
Decrease in blood cell counts, hair loss (reversible), constipation or abdominal
cramping, jaw pain, numbness or tingling in the ﬁngers or toes
Stanford Medicine – School of Medicine – Stanford Cancer Center – Understanding Cancer.
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are, therefore, more accurately classiﬁed as anti-proliferative,
rather than anti-cancer agents. The therapeutic window associ-
ated with differential responses between tumor cells and normal
dividing cells is based on differences in proliferation rates and
recovery parameters that may favor the tumor target, particularly
in fast growing malignancies. These differences in normal versus
tumor cell sensitivity to agents that block cell division, however,
are insufﬁcient to prevent cytotoxic side effects in normal bone
marrow and normal dividing epithelial cells. These overlapping
sensitivities ultimately limit the MTD, which may be insufﬁcient
to destroy all tumor cells without causing irreparable damage to
normal host tissue. Moreover, the ablation of the bone marrow
has a signiﬁcant effect on the immune system, at least temporar-
ily decreasing its capacity to defend against the malignant growth
within the body.
The vast majority of chemotherapy drugs used in “standard
of care” oncology practice for the treatment of advanced cancers
have a mechanism of action deﬁned by the cell kill paradigm.
The cell kill hypothesis originated with Skipper based on studies
of L1210 mouse (Skipper et al., 1965; Skipper and Perry, 1970).
The cell kill hypothesis states that a speciﬁc dose of drug kills
a constant fraction of cells rather than a speciﬁc number. Its
incremental success, therefore, depends on the number of cells
at the start of the treatment. The cell kill hypothesis ultimately
became the theoretical rationale for the implementation of high-
dose chemotherapy treatment regimens (Norton, 1985, 1988).
This conceptual approach was further enabled by the develop-
ment of autologous peripheral stem cell procedures in the 1980s
and 1990s that involve dose-dense chemotherapy in conjunction
with ablation of the bonemarrow and immune system followed by
autologous peripheral stem cell rescue. This approach represents a
full-scale application of the cell kill paradigm that has been widely
used to treat many types of advanced systemic cancers. Unfor-
tunately, application of this therapeutic approach to solid tumor
malignancies has not generally produced similar success rates. The
primary reason is that the cell kill paradigm cannot be applied to
the kinetics of solid tumor growth.
DIGGING DEEPER: GROWTH PARAMETERS OF SOLID
TUMORS CAUSE CHEMOTHERAPY RESISTANCE
The narrow therapeutic window limits the MTD of cytotoxic
chemotherapy drugs that target dividing cells. A very important
side effect of this limitation is that the rate of cell division in the
interior regions of solid tumors is frequently extremely low, lower
than normal dividing cells, thereby bypassing the cytotoxic effects
of these drugs even at their MTDs. What accounts for the low rate
of cell division in the solid tumor? The answer can be found in
the abnormal microenvironment that develops as the solid tumor
mass enlarges.
The clinical use of most conventional chemotherapy drugs
involves the basic assumption that the cancer phenotype is char-
acterized by continuous dysregulated cell proliferation. However,
research on tumor cell biology suggests that many solid tumors
of diverse tissue types are heterogeneous collections of cells that
are not consistently or uniformly proliferating at any given time
(Norton et al., 1976; Norton, 1985, 1988). Fundamental differ-
ence between the growth properties of leukemias/lymphomas
and solid tumors may explain key differences in chemotherapy
sensitivities.
The biological properties of solid tumors generally differ sig-
niﬁcantly from those of the disseminated cancers and profoundly
affect critical therapeutic parameters (Nederman and Carlsson,
1984; Tunggal et al., 1999; Tannock et al., 2002). One of the
most important differences, as it relates to sensitivity to cell cycle
inhibitors, involves theheterogeneousproliferation rates that char-
acterize solid tumors (Lupi et al., 2004). Unlike leukemic cells that
are released from the bone marrow at a premature stage of dif-
ferentiation and disseminated in the circulation, in solid tumors
transformed cells originate and proliferate as a solid mass at a
speciﬁc site of origin (at least, prior to metastasis) generating
abnormal,multi-dimensional structures that produce a distinctive
microenvironment associated with unique biophysical, biochemi-
cal, and physiological properties (Teicher et al., 1990; Kerbel et al.,
1996; Vaupel, 2004; Kozusko et al., 2007). Differential localization
of cells within a solid tumor give rise to marked gradients in the
rate of cell proliferation as a result of decreasing diffusion rates
for oxygen, nutrients, and growth factors associated with absent
or abnormal vascularization of the solid tumor interior (Hirst and
Denekamp, 1979; Vaupel et al., 1989; Kinzler andVogelstein, 1998;
Ljungkvist et al., 2002; Roskelley and Bissell, 2002; see Figure 7).
This results in regions of hypoxia and acidity that can also inﬂu-
ence the sensitivity of the tumor cells to drug treatment (Durand,
1986; Olive and Durand, 1994; Lankelma et al., 1999).
Tumor geometry and the altered microenvironment that result
from solid tumor growth may thus play critical roles in the resis-
tance of solid tumors to chemotherapy and must be included
in any relevant discussion of potential strategies to improve
the effectiveness of drug treatment of solid tumor malignan-
cies. Unfortunately, application of this therapeutic approach to
solid tumor malignancies has not generally produced similar suc-
cess rates. The primary reason is that the cell kill paradigm
FIGURE 7 | Growth fraction model suggests that tumors consist of
pools of both proliferating and non-proliferating cells, with only the
former category possessing the intrinsic biological capacity to respond
to drugs that specifically target dividing cells. Differential localization of
cells within a solid tumor give rise to marked gradients in the rate of cell
proliferation as a result of decreasing diffusion rates for oxygen, nutrients,
and growth factors-associated abnormal vascularization of the solid tumor
interior. Intrinsic chemotherapy resistance results when non-dividing cancer
cells do not respond to S- and M-phase chemotherapy drugs that block cell
proliferation by virtue of the fact that they are not in either the S- or M-phase
of the cell cycle at the time of treatment (Komarova andWodarz, 2005).
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cannot be applied to the kinetics of solid tumor growth. The
cell kill paradigm as reﬂected in the clinical use of most conven-
tional chemotherapy drugs involves the basic assumption that the
cancer phenotype is characterized by continuous dysregulated cell
proliferation. However, research on tumor cell biology suggests
that many solid tumors of diverse tissue types are heterogeneous
collections of cells that are not consistently or uniformly prolifer-
ating at any given time (Norton et al., 1976; Norton, 1985, 1988;
Lupi et al., 2004). These biological properties of solid tumors gen-
erally differ signiﬁcantly from those of the disseminated cancers
and profoundly affect critical therapeutic parameters (Nederman
and Carlsson, 1984; Tunggal et al., 1999; Tannock et al., 2002).
Unlike leukemic cells that are released from the bone marrow at a
premature stage of differentiation and disseminated in the circula-
tion, in solid tumors transformed cells originate and proliferate as
a solid mass at a speciﬁc site of origin (at least, prior to metastasis)
generating abnormal, multi-dimensional structures that produce
a distinctive microenvironment associated with unique biophysi-
cal, biochemical, and physiological properties (Teicher et al., 1990;
Kerbel et al., 1996; Vaupel, 2004; Kozusko et al., 2007). Differen-
tial localization of cells within a solid tumor give rise to marked
gradients in the rate of cell proliferation as a result of decreasing
diffusion rates for oxygen, nutrients, and growth factors associ-
ated with absent or abnormal vascularization of the solid tumor
interior (Hirst and Denekamp, 1979; Vaupel et al., 1989; Kinzler
and Vogelstein, 1998; Ljungkvist et al., 2002; Roskelley and Bis-
sell, 2002). This results in regions of hypoxia and acidity that
can also inﬂuence the sensitivity of the tumor cells to drug treat-
ment (Durand, 1986; Olive and Durand, 1994; Lankelma et al.,
1999). Tumor geometry and the altered microenvironment that
results from solid tumor growth may thus play critical roles in the
resistance of solid tumors to chemotherapy and must be included
in any relevant discussion of potential strategies to improve the
effectiveness of drug treatment of solid tumor malignancies.
LEUKEMIAS/LYMOHOMAS VERSUS SOLID TUMORS:
DIFFERENT DISEASE REQUIRE DIFFERENT
THERAPEUTIC APPROACHES
A critical historical development in cancer treatment approaches
involved the wholesale application of chemotherapy drugs used
in the successful treatment of some cancers arising in the retic-
uloendothelial system (i.e., leukemias and lymphomas) to the
treatment of solid tumormalignancies (Panetta et al., 2006). These
therapeutic protocols were developed initially in the context of
treating childhood leukemias and lymphomas; their extended clin-
ical applications to the treatment of solid tumormalignancieswere
based largely on the therapeutic successes observed, for exam-
ple, in the treatment of HD and acute lymphoblastic childhood
leukemia (ALL). In this context, therapeutic modeling in solid
tumors was largely based on the growth parameters deﬁned by the
growth of leukemia cells (Kim and Tannock, 2005). However, the
vast differences in growth properties that distinguish solid tumor
growth from that of the leukemias and some lymphomasmade this
translational approach inappropriate. Leukemias and solid tumor
malignancies are very different biological entities. Although they
share similar growth properties in that all types of cancer ulti-
mately suffer from regulatory dysfunction in proliferation that
is often associated with blocks to cell differentiation pathways,
nevertheless, solid tumor malignancies have a biology that is sig-
niﬁcantly different from that of the disseminated malignancies.
The primary therapeutic target in the leukemias/lymphomas is the
abnormal cancer stem cell population of the bone marrow/lymph
node. This target is more amenable to treatment with cytotoxic
drugs that block cell cycle proliferation than are solid tumors, as
the propagation of abnormally dividing cells comprises the pri-
mary cancer phenotype. In contrast, solid tumor malignancies
arise and accumulate as abnormal masses of growth dysregulated
cells enmeshed in the tissue of origin. These tumor masses, as
well as their metastatic counterparts, develop a phenotype that is
a product not only of genetically induced cell cycle dysregulation,
but also as a consequence of the abnormal microenvironment cre-
ated by the tumor mass (Durand, 1986; Olive and Durand, 1994).
The net result is a tumor whose proliferative capacity is gener-
ally restricted to its outer margins, thereby seriously limiting the
potential efﬁcacy of cancer drugs that target dividing cells. More-
over, the abnormal microenvironment presents a barrier to drug
uptake and critical mechanisms of action that depend on reac-
tive oxygen species (ROS) production (Pouyssegur et al., 2006).
Most importantly, solid tumor growth generates an abnormal reg-
ulatory equilibrium in which tumor survival depends less on the
sustained activation of a small subset of dysregulated genes but
rather on the epigenetic effects of the tumor microenvironment
that ultimately sustain tumor survival and spread (Lankelma et al.,
1999; Roskelley and Bissell, 2002). The biological selection param-
eters that drive this abnormal equilibriummay deﬁne limits on the
potential efﬁcacy of therapeutics designed to attack solid tumor
growth and survival by abrogating the activities of selected dys-
regulated genes that drive tumor initiation but may exercise only
a limited role in sustaining systemic disease progression (; Suther-
land et al., 1979; West et al., 1980; Wibe, 1980; Coley et al., 1993;
Kuh et al., 1999; Au et al., 2002; Grantab et al., 2006; Minchinton
and Tannock, 2006; Di Paolo and Bocci, 2007).
GROWTH FRACTION AND THE SOLID TUMOR PHENOTYPE
Mendelssohn’s concept of deﬁned growth fraction attempts to
deﬁne the kinetic basis for observed non-exponential growth pat-
terns of many human cancers (Mendelsohn, 1961). This concept
postulates that a tumor cell population simply consists of two
pools: one that is proliferating and one that is not proliferating. A
proposed explanation for why many human tumors do not pro-
liferate exponentially or, therefore, respond to anti-chemotherapy
drugs that block cell proliferation by ﬁrst order kinetics is based
this overall difference in cell division rates between normal and
tumor cells expressed as the tumor growth fraction. Gompertz
(1825) was the ﬁrst to propose a non-exponential growth pattern
to characterize the growth behavior of human cancers (Norton
et al., 1976; Norton and Simon, 1977a,b; Norton, 1988; Abbott
and Michor, 2006; Kozusko et al., 2007). He argued that tumors
essentially grow in a sigmoidal pattern such that the fastest growth
rate is observed when tumors are about one third of their max-
imum size (volume) and that slower growth rates are observed
at either end of the growth curve. This theory suggests that
small tumors and micro-metastases should be more sensitive
to cell division inhibitors used in chemotherapy because their
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growth rates are higher than very large tumors and, therefore,
at a stage more sensitive to the cytotoxic effects of agents that
block cell proliferation. This prediction, however, has not been
borne out in clinical and pre-clinical observations of small volume
tumor/micro-metastases sensitivity parameters to S- andM-phase
inhibitors, as they often display a drug-resistant phenotype (Tan-
nock, 1978; Abbott and Michor, 2006). It is generally accepted
that these micrometastatic lesions display chemosensitivity pat-
terns resulting from acquired resistance mechanisms observed
subsequent to primary chemotherapy-induced remissions.
This issue of tumor cell division rates and its relationship to
cancer drugs that speciﬁcally target cycling cells with respect to
the problem of drug resistancemay, therefore, in part be explained
by the growth fraction model that suggests that tumors consist of
pools of both proliferating and non-proliferating cells, with only
the former category possessing the intrinsic biological capacity to
respond to drugs that speciﬁcally target dividing cells (Kozusko
et al., 2007). In this context, intrinsic chemotherapy resistance can
be deﬁned as the failure of non-dividing cancer cells to respond
to S- and M-phase chemotherapy drugs that block cell prolifer-
ation by virtue of the fact that they are not in either the S- or
M-phase of the cell cycle at the time of treatment (Komarova and
Wodarz, 2005).
The biological parameters responsible for the growth behav-
ior of solid tumors, as deﬁned by the growth fraction, may be
explained in part by the observed growth behavior of micro-
metastases in vitro that follow spheroidal growth parameters of
volumetric increases that create a changing environment sur-
rounding the cells of the tumor, depending upon their location
within the solid tumor (Sutherland et al., 1979; West et al., 1980;
Wibe, 1980; Kuh et al., 1999). At the exterior, there is a shell of
proliferating cells up to ﬁve to six layers that are directly exposed
to physiological levels of growth factors, nutrients, and oxygen.
These parameters change as cells of the interior layers of the
tumor comprising the so-called “middle layer” experience some
degree of deprivation of these growth stimulants based on avascu-
lar diffusion rates as these factors move through the tumor layers.
The decreased availability of nutrients, growth factors and oxygen
block cell proliferation within this middle layer, that neverthe-
less, remains substantively viable (Sutherland et al., 1979; Coley
et al., 1993; Tannock et al., 2002). At the deepest internal layers
of the tumor, the innermost core often becomes necrotic due to
very low-level exposure to oxygen and nutrients. This model of
tumor growth for small (1–3 mm) avascular tumor masses may
explain some aspects of drug resistance based on the fact that the
use of cell cycle inhibitors would be expected to destroy selectively
the outermost proliferating shell of the tumor, but not have a
signiﬁcant effect on the inner non-proliferating cell layers that
comprise the bulk of the tumor mass. The biological basis of
growth fraction may thus reside in the geometry of spheroidal
growth and the local microenvironmental changes generated by
the developing tumor mass that may deﬁne cell proliferation rates
within the tumor and, concomitantly, intrinsic drug resistance
to conventional chemotherapy (Au et al., 2002; Grantab et al.,
2006).
A second component of solid tumor biology that may seri-
ously diminish the efﬁcacy of traditional cytotoxic chemotherapy
drugs is the unique microenvironment that develops during the
establishment of solid tumors. In addition to limiting the prolif-
erative capacity of tumor cells in the solid tumor interior, these
microenvironmental differences may directly contribute to tumor
resistance to the cytotoxic effects of these drugs (Minchinton and
Tannock, 2006; Di Paolo and Bocci, 2007). For example, as the
tumor interior becomes increasingly hypoxic due to poor and inef-
ﬁcient vascularization, resistance to death pathways that depend
on the production of oxygen free radicals may produce a drug-
resistant phenotype (Hirst and Denekamp, 1979; Ljungkvist et al.,
2002). This may be extremely relevant to the problem of drug
resistance as many S-phase inhibitors that damage DNA (and
also therapeutic radiation) rely upon free radical production as
a primary pathway to induce cell death; therefore, this microenvi-
ronmental component of solid tumorsmay be an important factor
limiting the toxic effects of these therapeutic agents (Vaupel et al.,
1989; Bussink and van der Kogel, 2003; Koukourakis et al., 2006).
NEW PARADIGM: INFLAMMATION AND REACTIVE OXYGEN
SPECIES UNDER ATTACK
The limited and inconsistent success rate resulting from the cur-
rent treatment regimens ofmany cancers needs to be strengthened.
How do we go about doing this in a way that will make the most
sense, based upon our understanding of cancer biology, the lessons
that wemay take frommore than a half-century of therapy involv-
ing the use of traditional chemotherapeutic drugs and the newer,
targeted biologic drugs? This new therapeutic paradigm represents
a synthesis of what is currently understood about the biological
processes that lead to the development of malignancies and the
results that have been obtained from therapeutic and preventive
studies that have been ongoing for the past half-century, highlight-
ing those approaches which appear to have met with the greatest
success in identifying potential reliable approaches that might be
exploited for therapeutic purposes over the next decade.
INFLAMMATION
Researchers have long understood that there is a relationship
between inﬂammation and cancer, though the mechanisms
involved were obscure. Rudolf Virchow was one of the ﬁrst biolo-
gists to suggest this association in the 19th century. More recently,
inﬂammatory pathways associated with the development of some
of the most common cancers have been elaborated and explained
at the molecular level. Major risk factors for the most common
cancers include chronic infection, obesity, alcohol, tobacco, radia-
tion, high calorie diets, and environmental pollutants. Moreover,
each of these risk factors has been shown to contribute to can-
cer development vis-a-vis inﬂammatory processes. Research has
shown that long-term inﬂammation has been linked to most
chronic illnesses: cancer, cardiovascular disease, diabetes and obe-
sity (Braun et al., 2009; Khandekar et al., 2011). There is substantial
evidence that many cancers, especially solid tumors such as colon
cancer andpancreatic cancer, are precededby inﬂammationwithin
the organ in which the cancer arises (Rolland et al., 1980; Kune
et al., 1988; Coussens andWerb, 2002; Farrow and Evers, 2002; Pai
et al., 2002; MacArthur et al., 2004; Nelson et al., 2004; Philip et al.,
2004). For example, 15–20% of smokers with chronic obstruc-
tive pulmonary disease will develop lung cancer (Turner et al.,
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2007). Colitis is associated with high risk of colon cancer; infec-
tion with H. pylori is linked to stomach cancer (Pai et al., 2002;
Peek and Blaser, 2002; Itzkowitz and Yio, 2004; MacArthur et al.,
2004). These and other research studies have shown that chronic
inﬂammation precedes the development of many types of cancer,
and that inﬂammatory pathways are constitutively active in most
cancers (Rolland et al., 1980).
Most of the risk factors associatedwith inﬂammation have been
to shown to activate NF-kB (nuclear factor-kappaB) and STAT-3
(signal transducer and activator of transcription 3), major tran-
scription factors that regulate inﬂammatory pathways (Ivanenkov
et al., 2011). NF-kB was discovered in lymphoid cells in 1986 and
ultimately found to be a ubiquitous transcription factor found in
all cells (Sen and Baltimore, 1986). STAT-3 is a transcriptional
regulator found in the cytoplasm of most cells and is activated in
response to certain inﬂammatory stimuli resulting in the produc-
tion of gene products such as the BCL-XL (B-cell lymphoma-extra
large) and other growth factors; most recently, dysregulated func-
tion of STAT-3 has been linked to cancer metastasis (Deng et al.,
2012). Most agents that promote inﬂammation activate NF-
kB, including endotoxins, carcinogens, radiation, chemotherapy,
hyperglycemia, tumor promoters, inﬂammatory cytokines [e.g.,
tumor necrosis factor (TNF), interleukin 1 (IL-1)], and growth
factors such as epidermal growth factor (EGF). In addition, almost
all infectious agents associated with cancer activate NF-kB, includ-
ing human papilloma virus (HPV), human herpesvirus (HHV),
hepatitis B virus (HBV), and hepatitis C virus (HCV; Peek and
Blaser, 2002; Itzkowitz and Yio, 2004).
Pro-inﬂammatory stimuli such as TNF, IL-1 and IL-6, cyclo-
oxygenase-2 (COX-2), and lipoxygenase (LOX) all regulate NF-kB
and are expressed in bronchitis, colitis, gastritis, and hepatitis
(Philip et al., 2004). Moreover, chemotherapy and radiation acti-
vate NF-kB, which subsequently contributes to acquired chemo-
resistance. Tumor pathways associatedwith survival, proliferation,
invasion, and metastasis are all important activators of NF-kB
(MacArthur et al., 2004) in positive feedback loop mechanisms
that may drive advanced cancer progression. Based on a large vol-
ume of research data, including the aforementioned and other
studies, one may conclude that most gene products associated
with inﬂammation can contribute to cancer development as well
as progression; survival, proliferation, invasion, angiogenesis,
and metastasis, all of which are regulated by NF-kB and STAT-3
(Rolland et al., 1980; Sheng et al., 2001; Pai et al., 2002; Chang
et al., 2004).
Much recent attention has focused on the long-term use of
anti-inﬂammatory drugs such as aspirin as cancer preventives.
The association between chronic inﬂammation and inﬂammatory
pathway activation in the genesis of cancer is supported by clinical
research studies that provide evidence for the preventive aspects of
long-term aspirin use in the development of some commonmalig-
nancies, including breast, colon cancer, bladder cancer,melanoma,
and other cancers (Castelao et al., 2000; Sharpe et al., 2000; Ander-
son et al., 2002; Thun et al., 2002; Pereg and Lishner, 2005; Ulrich
et al., 2006; Annemijn et al., 2012). This preventive effect has even
been documented in individuals at high risk for developing colon
cancer due to inherited geneticmutations (Ulrich et al., 2006; Burn
et al., 2011; Chan and Lippman, 2011).
Additional research studies suggest that suppression of inﬂam-
matory pathways may be involved in both the prevention and
treatment of cancer (Sharpe et al., 2000; Anderson et al., 2002;
Thun et al., 2002; Baek and Eling, 2006; Eling et al., 2006). Sup-
pression of the NF-kB regulator, IKKB (inhibitor of kappaB kinase
beta), and STAT-3 have been shown to block tumor proliferation
and invasion (Pereg and Lishner, 2005). Diﬂuoromethylornithine
and sulindac were shown to reduce the risk of colorectal adenoma
recurrence by 70%.
Several recently published studies have provided further evi-
dence for preventive and therapeutic effects of daily aspirin.
Longitudinal studies have shown that long-term daily aspirin use
for at least 10 years reduces the risk of developing colon cancer and
other common cancers. These clinical data indicated that low-dose
aspirin use for at least 3 years can reduce the risk of cancer inci-
dence by about 25% and the risk of dying from cancer by about
15%. The statistic increases from 25 to 37% for those who take
aspirin for longer than 5 years (Rothwell et al., 2012). The results
of these studies showed that aspirin use helped prevent the spread
or metastasis of cancer to other organs (Annemijn et al., 2012;
Rothwell et al., 2012). These data suggested that long-term daily
aspirin use reduced the proportion of cancers that spread system-
ically by 48%. Moreover, use of anti-inﬂammatory drugs reduced
the risk of being diagnosed with a solid cancer that had already
spread by 31%. For patients initially diagnosed with a local cancer,
the risk of later metastasis was reduced by 55% by daily high-dose
aspirin usage. The study authors suggested that at least part of
this preventive effect may be linked to the effects of aspirin on
platelets. Moreover, the authors suggested that theirs was the ﬁrst
study to show that ANY drug could reduce metastasis as a speciﬁc
drug-induced effect.
Additional natural products with demonstrated anti-cancer
activity that also block inﬂammation via NF-kB pathway inhibi-
tion include curcumin, resveratrol, ursolic acid, andothers (Huang
et al., 1994; Jang et al., 1997). For example, in human clinical tri-
als, curcumin was shown to down-regulate NF-kB and STAT-3
and is thought to have potential for the prevention and/or treat-
ment of pancreatic cancer, familial adenomatous polyposis (FAP),
inﬂammatory bowel disease, durable bowel disease, and other
pro-inﬂammatory diseases. In addition, research studies have sug-
gested that many cancer preventive agents mediate their effects
through inhibition of NF-kB and STAT-3 (Baek and Eling, 2006).
ANTI-OXIDANTS AND CANCER THERAPY
The potential preventive anti-cancer effects of anti-oxidants found
in high concentrations in many phytochemicals have become a
major focus of research in recent years. Despite accumulating evi-
dence to suggest an important role in cancer prevention, there
has been much controversy over their potential therapeutic appli-
cations based on the fact that these agents block free radical
formation as an important mediator of their anti-cancer effects
(Stamatakos et al., 2006). Although free radicals may be impor-
tant intracellular carcinogens, nevertheless, the formation of free
radicals may mediate the cytotoxic tumor cell killing activities of
many standard chemotherapy drugs as well as radiation (Block,
2004; D’Andrea, 2005). Among the barriers to conventional ther-
apy presented by the tumor microenvironment, it is well-known
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that hypoxia inhibits effective radiation killing, due to its limit-
ing effects on the production of ROS (Komarova and Wodarz,
2005). In addition, chemotherapy resistance associated with low
oxygen concentrations affects the activity of drugs such as mel-
phalen, bleomycin, and etoposide, all of which require molecular
oxygen for their cell killing effects. Research on chemotherapy
resistance further suggests that stem cells with low concentrations
of ROSmay be an important cause of treatment failure (Achuthan
et al., 2011). Hypoxia can also induce cell cycle arrest and resis-
tance to apoptosis, both of which can dramatically decrease the
efﬁcacy of drugs that target proliferating cells (Michor et al., 2005;
Kozusko et al., 2007). That said, the purpose of this discussion is
not to explore the potential use of anti-oxidants in the context of
their potential inhibitory effects when used in conjunction with
cytotoxic chemotherapy or radiation, but rather to explore other
potentially important relationships between anti-oxidant activity
and cancer as they relate to the development of incipient cancers
and tumor progression.
To address this question, it is necessary to explore the bio-
logical basis of the potential anti-cancer therapeutic effects of
anti-oxidants. Of particular importance is the question of whether
anti-oxidants can prevent the formation of incipient tumors
and/or affect parameters of tumor growth behavior involving
ROS (Kennedy, 1987; Wardman, 2001; Brown and Wilson, 2004).
Abnormal tumor vasculature is a primary cause of hypoxia, intra-
tumoral acidic conditions and increased interstitial ﬂuid pressure
(IFP) of the tumor microenvironment (Boucher et al., 1990).
Moreover, based on their effects on mitochondrial function, it
is entirely possible that the formation of oxygen free radicals may
contribute to the development of tumor-associated hypoxia as a
result of mitochondrial dysfunction. Normal PO2 oxygen ranges
between 10 and 80 mmHg; many solid tumors contain PO2 at less
than 5mmHg. Elevated tumor acidity compared to normal tissues
is associated with lactate accumulation due to the spacio-temporal
pH gradients resulting from the metabolic state of tumor cells and
the ion pumping mechanisms that vary signiﬁcantly in tumors
(Bonuccelli et al., 2010a; Pavlides et al., 2010a). The resulting acti-
vation of hypoxia inducible factor (HIF-1a) (Wang and Semenza,
1995) is associated with solid tumor progression and has been
shown to drive many of the survival and metastatic pathways that
are characteristic of advanceddisease (Martinez-Outschoorn et al.,
2010a,c).
Under normal physiological conditions, a small fraction of oxy-
gen consumed bymitochondria is converted to superoxide anions,
H2O2, hydroxyl radicals, and other ROS. Within speciﬁc con-
centration limits, ROS regulate cell functions, acting as a second
messenger to activate transcription factors NF-kB and activator
protein 1 (AP-1). Excess ROS production, however, is destruc-
tive. Overproduction of ROS by damaged mitochondria may
activate inﬂammatory pathways linked to cancer (Lisanti et al.,
2010; Martinez-Outschoorn et al., 2010c; Pavlides et al., 2010b;
Toullec et al., 2010). Moreover, mitochondrial production of ROS
as a byproduct of oxidative respiration is accelerated by the aging
process. Impairment of the electron transport chain results in
enhanced production of ROS in mitochondria due to incomplete
reduction of oxygen (Pavlides et al., 2010b). Anti-oxidants may
derail this process by blocking inﬂammatory responses to ROS
as well as by preventing the accumulation of intracellular ROS.
Anti-oxidant enzymes that block ROS are manganese glutathione
reductase (GR), catalase (CAT), manganese+2-dependent super-
oxide dismutase (MnSOD), copper zinc superoxide dismutase
(SODCu/Zn), and glutathione peroxidase (GPx; Bravard et al.,
1992; Behrend et al., 2005; Oberley, 2005; St. Clair et al., 2005).
Their activities decline with aging, resulting in age-dependent
damage toDNA,RNA, lipids, andproteins.Moreover, bioenergetic
functions decline with age. Oxidative damage to mitochondrial
DNA is much more extensive than to nuclear DNA and is asso-
ciated with increased glycolysis that may be blocked by glycolytic
inhibitors resulting in what has been called a “reverse Warburg
effect” (Pavlides et al., 2009; Bonuccelli et al., 2010b).
The overall result is elevated levels of oxidative stress. ROS may
induce stress responses to maintain energy metabolism, but at
high levels this causes broad-spectrum oxidative damage that may
elicit apoptosis by inducing membrane permeability changes in
mitochondria resulting in the release of cytochrome C. Oxidative
damage also produces deletions and duplications inmitochondrial
DNA, a process that increases with age in many human tissues,
further contributing tomitochondrial dysfunction. In this context,
mitochondria may be regarded as biosensors of oxidative stress in
the cell (Martinez-Outschoorn et al., 2010b).
Thus, there appears to be a cyclical interaction between mito-
chondrial respiration, which is an important source of ROS due
to electron leakage from the respiratory chain, and the destructive
effects of excessive ROS production on mitochondrial function
(seeFigure 8). Harman suggested thatmitochondria aremajor tar-
gets of free radical attack that leads to aging, a concept embodied
in the “free radical theory of aging.”Miquel and Bertoni-Freddari
(2000) showed that oxidative damage to mitochondrial DNA
and lipofuscin pigment formation concurrently increase in aging.
Linnane et al. (1989) hypothesized that the accumulation of
somatic mutations in mitochondrial DNA is a major contribu-
tor to aging and degenerative diseases, a concept embodied in
the “mitochondrial theory of aging.” Moreover, Bonuccelli et al.
(2010b) suggested that enhanced lactate and ketone production
from elevated glycolysis associated with depressed mitochon-
drial oxidative phosphorylationmay drive metastasis via oxidative
metabolism.
The loss of stromal caveolin-1 (Cav-1) has been linked to a
“reverse Warburg effect” (Warburg, 1956), resulting in autophagy
and mitophagy in tumor-associated ﬁbroblasts that provide addi-
tional energy-producing intermediates to tumor cells in the
microenvironment that support tumor growth (Pavlides et al.,
2009; Lisanti et al., 2010; Pavlides et al., 2010a,b,c) Moreover, low
levels of stromal Cav-1 is a biomarker for poor prognosis in
some common cancers, such as prostate cancer and breast can-
cer (Mercier et al., 2008; Di Vizio et al., 2009; Witkiewicz et al.,
2009a). In patients with triple negative breast (TNB) cancer, high
levels of stromal Cav-1 correlate with survival rates of over 75%
in 12 years. In contrast, TNB patients with very low levels of stro-
mal Cav-1 have a 5-year survival rate of less than 10% (Finak
et al., 2008; Sloan et al., 2009; Witkiewicz et al., 2009b, 2010).
In the context of this discussion, it should be noted that anti-
oxidants such as N-acetyl-cysteine, quercetin, and metformin as
well as chloroquine, which inhibits autophagy, have been shown to
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FIGURE 8 | Physiological connections that may link cancer prevention
and treatment. Excessive ROS (reactive oxygen species) due to aging or
environmental exposure damage mitochondria and promote glycolytic switch
characteristic of tumor cells. Inﬂammation and ROS activate NF-kB and other
transcription factors that drive tumor progression. Anti-inﬂammatory agents
and anti-oxidants prevent cancer by blocking systemic and
microenvironmental changes that promote incipient tumor development
and systemic disease progression. In the therapeutic setting, their long-term
use restores systemic environment that blocks disease progression and/or
recurrence.
prevent loss of stromal Cav-1 in tissue co-culture systems (Trim-
mer et al., 2011).
PREVENTION VERSUS TREATMENT: POTENTIAL
PHYSIOLOGICAL CONNECTIONS
There is increasing evidence that anti-oxidant activity may play
a role in suppressing the tumor phenotype. Suppression of
the glioma phenotype by Mn++SOD overexpression has been
reported (Zhong et al., 1997) as well as in SV40 transformed lung
ﬁbroblasts (Yan et al., 1996; Oberley, 2001). Additional research
suggests that up-regulation of Mn++SOD may be an important
target for anti-cancer therapeutics (Duan et al., 2003; Pani et al.,
2004; Venkataraman et al., 2005). With respect to anti-oxidant
effects on ROS-associated aging processes, research has shown
that oral administration of anti-oxidants protects rats and mice
from glutathione oxidation and mitochondrial damage. Addi-
tional researchﬁndings that strongly suggest that oxidative damage
results in mitochondrial defects in respiration and oxidative phos-
phorylation (Kovacic and Osuna, 2000; Wardman, 2001). Clearly,
more studies are needed in this area; however, these research
studies suggest that an important component of anti-oxidant pre-
ventivemay involve the preventionof ROS-inducedmitochondrial
damage, which contributes importantly not only to aging, but
also to cancer, perhaps by activating the glycolytic switch that
characterizes cancer cell metabolism.
One question that needs to be addressed in the context of devel-
oping a new therapeutic paradigm is whether agents that prevent
cancer by blocking inﬂammation may also act therapeutically by
preventing cancer spread and recurrence. Do agents that block
inﬂammation, such as aspirin, act only at the level of tumor
initiation by inhibiting inﬂammatory pathways that may con-
tribute to the development of an incipient pre-malignant state?
Or, is there evidence that their activities go beyond this to affect
pre-established malignant tumors within the body to block their
further progression? In other words, do disease progression and
the development of systemic disease require inﬂammatory pro-
cesses for their sustenance? The answer to these questions is a
probable“yes,”based on clinical data results (see previous section),
the observed cytotoxic effects of aspirin in cultured tumor cells,
and physiological assessments of the presence of elevated levels
of several biomarkers for inﬂammation in patients with many
types of advanced cancer. It is entirely possible that some of
the apparent chemopreventive properties of anti-inﬂammatory
agents may be operating at the level of pre-established incipient
malignancies in which further tumor progression and the onset
of overt disease are signiﬁcantly delayed or do not occur at all.
It is important to carry out studies to establish this possibility as
a rationale for the use of this approach in long-term, preventive
modalities. If so, then anti-inﬂammatory agents might be devel-
oped for use in long-term maintenance therapeutic approaches
in the management of malignant disease as well as in cancer
prevention.
The inclusion of long-term maintenance therapy involving the
use of any anti-inﬂammatories must be evaluated in this con-
text. The concept of long-term maintenance therapy approaches
to prevent disease recurrence is further supported by longitudi-
nal studies on the long-term use of tamoxifen and aromatase
inhibitors in the management of breast cancer (Early Breast
Cancer Trialists’ Collaborative Group et al., 2011). The consen-
sus of these clinical studies is that, despite the occurrence of
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side effects, these approaches may be life-saving in terms of
preventing disease recurrence by targeting growth factor and hor-
monally activated pathways important to sustaining tumor pro-
gression and abnormal growth pathways contributing to disease
recurrence.
Another point that should be emphasized involves the fact
that successful therapy with gene-targeted drugs such as Gleevec,
tamoxifen, and aromatase inhibitors requires ongoing treatment
involving a continuous dosing regimen that follows a very different
protocol from that generally followed in cytotoxic chemotherapy.
In the case of gene-targeted drugs such as Gleevec, the patient will
receive the drug on a long-term basis as a form of maintenance
therapy to prevent the establishment of drug-resistant clones.
The need for continuous maintenance therapy in the success-
ful management of patients with chronic myelogenous leukemia
(CML) using Gleevec suggests that successful cancer management
in general may require long-term maintenance therapy in order
to achieve stable remissions and to prevent the development of
acquired drug resistance. These clinical successes in long-term
cancer management underscore the importance of developing
therapeutic approaches that can be used in long-termmaintenance
therapy to prevent disease recurrence.
This approach, of course, is not possible using conventional
chemotherapeutics; due to their high-level toxicity, it would be
impossible to use cytotoxic drugs for long-term maintenance
therapy regimens. This, therefore, represents a basic therapeutic
modality that cannot be entertained in the context of conventional
chemotherapy drugs. Nevertheless, the successful management of
many types of cancer may require an approach that involves some
type of long-term maintenance therapy in order to prevent dis-
ease recurrence. An important therapeutic goal for future research,
therefore, may involve the development of therapeutics designed
for use in long-term maintenance therapy. These agents, though
speciﬁc in their cell-targeted inhibitory effects, nevertheless impact
essential pathways that drive the malignant phenotype. Perhaps
nothing less will do.
The concepts of anti-inﬂammatory and anti-oxidant
approaches to cancer therapy involve a very basic hypothesis, that
similar mechanisms may be associated with their cancer preven-
tive effects and therapeutic effects. In other words, prevention and
treatmentmay not be two different entities but rathermay bemul-
tifaceted components necessary to create a systemic environment
that prevents both the development and spread of malignancies
within the body. By altering the tumor-promoting environment,
either in pre-malignant, active or post-malignant conditions, these
so-called preventive agents may help to maintain a system equi-
librium that is resistant both to tumor development and disease
recurrence. The paradigm that prevention and treatment are
interconnected therapeutic approaches is based on the proposed
interrelationship betweenphysiological conditions associatedwith
the development of incipient cancer and the progression to sys-
temic disease. This paradigm suggests that the treatment of
cancer is not simply regarded as a short-term effort to destroy
tumor cells in patients with diagnosed disease but rather as both
a preventive approach in healthy individuals to protect against
the development of incipient cancers and also as a therapeutic
approach in diagnosed patients to modify the system in such a
way that the host no longer serves to support tumor growth within
the body.
CONCLUSION
For the past several decades, the prevailing therapeutic paradigm
for the treatment of both disseminated leukemias/lymphomas as
well as almost all solid tumor malignancies has involved the use
of dose-dense, combined MTD cytotoxic chemotherapy. Current
therapeutic protocols for the treatment ofmost cancerswere devel-
oped initially in the context of treating childhood leukemias and
lymphomas; their extended clinical applications to the treatment
of solid tumor malignancies were based largely on the therapeutic
successes observed, for example, in the treatment of HD and acute
lymphoblastic childhood leukemia (ALL).
Despite these broad-spectrum applications to almost all cur-
rently used chemotherapy regimens, in only a few types of cancer
do we see curative responses such as have been consistently
observed in the treatment of childhood ALL and HD. Thus, the
results of over a half-century of clinical trials have shown that
the therapeutic approach of combined/dose-dense chemotherapy
has not been successful in achieving its primary purpose, which is
the induction of long-term disease-free survival in the majority of
patients with systemic disease.
The clinical use of most conventional chemotherapy drugs
involves the basic assumption that the cancer phenotype is charac-
terized by continuous dysregulated cell proliferation. Therapeutic
modeling in solid tumors was largely based on the growth param-
eters deﬁned by the growth of leukemia cells; however, the vast
differences in growth properties that distinguish solid tumor
growth from that of leukemias and some lymphomas made this
translational approach inappropriate. Research on tumor biol-
ogy suggests that many solid tumors of diverse tissue types are
heterogeneous collections of cells that are not consistently or
uniformly proliferating at any given time. Fundamental differ-
ences between the growthproperties of leukemias/lymphomas and
solid tumors may thus explain key differences in chemotherapy
sensitivities.
The association between chronic inﬂammation and ROS activ-
ity in the genesis of cancer is supported by clinical research studies
that provide evidence for the preventive aspects of the long-term
use of aspirin and anti-oxidants in the development of some
common malignancies. Moreover, based on their effects on mito-
chondrial function, it is entirely possible that inﬂammation/ROS
may contribute to abnormal tumor physiology that promotes
tumor progression and metastasis.
The concept of long-term anti-inﬂammatory/anti-oxidant
maintenance approaches to cancer therapy involves a very basic
hypothesis, that similar physiological mechanismsmay be respon-
sible for both cancer preventive and therapeutic effects. Prevention
and treatment may not be two different entities but rather may
be multifaceted components necessary to create a systemic envi-
ronment that prevents both the development and spread of
malignancies within the body. By altering the tumor-promoting
environment, either in pre-malignant, active or post-malignant
conditions, these so-called preventive agents may help tomaintain
a system equilibrium that is resistant both to tumor development
and disease recurrence.
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